LIVING WITH HIGH BLOOD PRESSURE? YOU'RE NOT ALONE.

See if you qualify for the TARGET BP OFF-MED Clinical Trial

The TARGET BP OFF-MED Clinical Trial is evaluating the Peregrine Procedure, a minimally invasive intervention that has been shown in early studies(6,7) to reduce blood pressure by deactivating specific nerves surrounding the renal (kidney) arteries that, through over-signaling, can contribute to high blood pressure.   

 

The Peregrine Procedure is performed under mild sedation. The Peregrine Catheter will be advanced through a small incision in the groin and guided up to the renal arteries using angiography (like an X-ray). The system will deliver a small dose of dehydrated alcohol to the region just outside the artery where these sympathetic nerves are located, to deactivate their over-signaling. 

Participation in the TARGET BP OFF-MED Clinical Trial could help clinicians understand the potential benefits of an innovative therapy that may help reduce blood pressure. The results of the research may help with the treatment of this condition. If interested in learning more, follow the “Learn More About Trial Participation” link.

1) Bloch, Michael J, Worldwide prevalence of hypertension exceeds 1.3 billion, Journal of the American Society of Hypertension 10(10) (2016) 753-754.

2) World Health Organization,  Q&A on Hypertension, Updated Sept. 2015  (information accessed 29Mar2018)  (www.who.int/features/qa/82/en/)

3) World Health Organization,  Q&A on Hypertension, Updated Sept. 2015  (information accessed 29Mar2018)  (www.who.int/features/qa/82/en/)

4) Lobo, Sobotka and Pathak, Clinical Update – Interventional procedures and future drug therapy for hypertension, European Heart Journal (2017) 38,1101-1111.

5) Mahfoud et al, Proceedings from the 2nd European Clinical Consensus Conference for device-based therapies for hypertension: state of the art and considerations for the future, European Heart Journal (2017) 38, 3272-3281

6) Fischell et al, Transcatheter Alcohol-Mediated Perivascular Renal Denervation with the Peregrine System: First-in-Human Experience, J Am Coll Cardiol Intv 2016; 9:589-98   (March 28,  2016)

7) Bertog et al, CRT-200.21 Alcohol-mediated Renal Denervation to Treat Hypertension – The Peregrine Post-market Study, J Am Coll Cardiol Intv 2018; 11: S32-S33.  (26 Feb 2018).

8) Mancia et al, 2013 ESH/ESC Guidelines for the management of arterial hypertension, Journal of Hypertension 2013, 31:1281–1357

9) Mahfoud et al, Proceedings from the 2nd European Clinical Consensus Conference for device-based therapies for hypertension: state of the art and considerations for the future, European Heart Journal (2017) 38, 3272-3281

10) Lobo, Sobotka and Pathak, Clinical Update – Interventional procedures and future drug therapy for hypertension, European Heart Journal (2017) 38,1101-1111.

11) Mahfoud et al, Proceedings from the 2nd European Clinical Consensus Conference for device-based therapies for hypertension: state of the art and considerations for the future, European Heart Journal (2017) 38, 3272-3281

12) Bertog et al, CRT-200.21 Alcohol-mediated Renal Denervation to Treat Hypertension – The Peregrine Post-market Study, J Am Coll Cardiol Intv 2018; 11: S32-S33.  (26 Feb 2018).

13) Mahfoud, Felix, Chemical Renal Denervation with Ethanol – Update for a Promising Technology, Presentation at CRT March 2018.(www.crtonline.org/crt-premium) 

14) Fischell et al, Transcatheter Alcohol-Mediated Perivascular Renal Denervation with the Peregrine System: First-in-Human Experience, J Am Coll Cardiol Intv 2016; 9:589-98   (March 28,  2016)